Prognostic Implications of Mid-Range Left Ventricular Ejection Fraction on Patients Presenting With ST-Segment Elevation Myocardial Infarction

被引:35
作者
Margolis, Gilad [1 ]
Khoury, Shafik [1 ]
Ben-Shoshan, Jeremy [1 ]
Letourneau-Shesaf, Sevan [1 ]
Flint, Nir [1 ]
Keren, Gad [1 ]
Shacham, Yacov [1 ]
机构
[1] Tel Aviv Univ, Dept Cardiol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Tel Aviv, Israel
关键词
PERCUTANEOUS CORONARY INTERVENTION; THROMBOLYTIC THERAPY; HEART-FAILURE; DYSFUNCTION; CAPTOPRIL; MORTALITY; SURVIVAL; MORBIDITY; RECOVERY; OUTCOMES;
D O I
10.1016/j.amjcard.2017.04.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The new European Society of Cardiology guidelines reclassified heart failure according to left ventricular ejection fraction, recognizing patients with mid-range EF (mrEF; 40% to 49%) as a distinct group. We sought to investigate the clinical profile, in-hospital outcomes, and long-term mortality of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention who had mrEF. We conducted a retrospective study of 2,086 consecutive patients with STEMI between December 2007 and June 2016 who underwent primary percutaneous coronary intervention and had a comprehensive echocardiographic examination performed within 72 hours of hospital admission. Patients were stratified according to their left ventricular ejection fraction-mrEF (40% to 49%), reduced EF (rEF; <40%), and preserved EF (pEF; >= 50%) groups and evaluated for baseline characteristics, in-hospital outcomes, as well as for long-term mortality. A total of 858 of 2,086 patients (41%) had mrEF, 215 of 2086 (10%) had rEF, and 1,013 of 2,086 (48%) had pEF. Patients with mrEF had nearly similar baseline co-morbidities and similar 30-day mortality compared with patients with pEF (2% vs 1%, p = 0.17). In a univariate analysis, long-term mortality was higher compared with those with pEF (9.8% vs 7.2%, p <0.01). In a multivariate Cox regression model, mrEF was independently associated with increased long-term mortality risk compared with pEF (hazard ratio 1.4, 95% CI 1.02 to 1.93, p = 0.04). In conclusion, among STEMI patients, those with mrEF at presentation constitute a distinct group in terms of baseline characteristics, in-hospital outcomes, and long-term mortality. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:186 / 190
页数:5
相关论文
共 21 条
[1]   Red Blood Cell Distribution Width (RDW) and long-term survival in patients with ST Elevation Myocardial Infarction [J].
Arbel, Yaron ;
Shacham, Yacov ;
Finkelstein, Ariel ;
Halkin, Amir ;
Milwidsky, Assi ;
Berliner, Shlomo ;
Ziv-Baran, Tomer ;
Revivo, Miri ;
Herz, Itzhak ;
Keren, Gad ;
Banai, Shmuel .
THROMBOSIS RESEARCH, 2014, 134 (05) :976-979
[2]   The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis [J].
Burns, RJ ;
Gibbons, RJ ;
Yi, QL ;
Roberts, RS ;
Miller, TD ;
Schaer, GL ;
Anderson, JL ;
Yusuf, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (01) :30-36
[3]   Comparison of Three-Year Outcomes After Primary Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fraction &lt;40% Versus ≥40% (from the HORIZONS-AMI Trial) [J].
Daneault, Benoit ;
Genereux, Philippe ;
Kirtane, Ajay J. ;
Witzenbichler, Bernhard ;
Guagliumi, Giulio ;
Paradis, Jean-Michel ;
Fahy, Martin P. ;
Mehran, Roxana ;
Stone, Gregg W. .
AMERICAN JOURNAL OF CARDIOLOGY, 2013, 111 (01) :12-20
[4]   Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J].
Dargie, HJ ;
Colucci, Y ;
Ford, I ;
Sendon, JLL ;
Remme, W ;
Sharpe, N ;
Blank, A ;
Holcslaw, TL .
LANCET, 2001, 357 (9266) :1385-1390
[5]   Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomised trial [J].
Dickstein, K ;
Kjekshus, J .
LANCET, 2002, 360 (9335) :752-760
[6]   Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction - The CADILLAC risk score [J].
Halkin, A ;
Singh, M ;
Nikolsky, E ;
Grines, CL ;
Tcheng, JE ;
Garcia, E ;
Cox, DA ;
Turco, M ;
Stuckey, TD ;
Na, YG ;
Lansky, AJ ;
Gersh, BJ ;
O'Neill, WW ;
Mehran, R ;
Stone, GW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (09) :1397-1405
[7]   Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction [J].
Kapoor, John R. ;
Kapoor, Roger ;
Ju, Christine ;
Heidenreich, Paul A. ;
Eapen, Zubin J. ;
Hernandez, Adrian F. ;
Butler, Javed ;
Yancy, Clyde W. ;
Fonarow, Gregg C. .
JACC-HEART FAILURE, 2016, 4 (06) :464-472
[8]   A CLINICAL-TRIAL OF THE ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR TRANDOLAPRIL IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION [J].
KOBER, L ;
TORPPEDERSEN, C ;
CARLSEN, JE ;
BAGGER, H ;
ELIASEN, P ;
LYNGBORG, K ;
VIDEBEK, J ;
COLE, DS ;
AUCLERT, L ;
PAULY, NC ;
ALIOT, E ;
PERSSON, S ;
CAMM, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1670-1676
[9]   RISK STRATIFICATION AND SURVIVAL AFTER MYOCARDIAL-INFARCTION [J].
MOSS, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (06) :331-336
[10]  
Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350